52 results on '"Génestie C"'
Search Results
2. Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)
3. Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review
4. La préservation de fertilité en cas de cancer du col, analyse de 30 ans de pratique et immersion dans les évolutions à venir
5. Médecine de précision et immunoradiothérapie
6. Glassy cell carcinoma of the uterine cervix: 20-year experience from a comprehensive cancer center
7. Evaluation of adjuvant vaginal vault brachytherapy in early stage cervical cancer patients
8. Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy
9. Estrategias quirúrgicas en tumores limítrofes de ovario
10. Networking for ovarian rare tumors: a significant breakthrough improving disease management
11. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
12. 92P Tumour-infiltrating immune cells as a predictive factor in advanced or metastatic leiomyosarcomas: Comparison between uterine and non-uterine tumors
13. 59P Expression of CD47 a potent ‘don’t eat me signal' in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study
14. 773P Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials
15. Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab
16. 774P CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
17. MO-0050 Feasibility of the determination of the molecular-integrated risk profile in the PORTEC-4a trial
18. Cryoconservation de cortex ovarien chez la fille prépubère : indications et faisabilité
19. L'évaluation conjointe du contenu en ADN et de la fraction de cellules en phase S est un paramètre pronostique indépendant dans les cancers du sein de stades I et II
20. Association concomitante préopératoire de radiothérapie et de chimiothérapie dans les cancers du col utérin opérables de stades IB2, IIA et IIB proximal de gros volume
21. Cancer du sein localement évolué non inflammatoire traité par association de chimiothérapie et de radiothérapie à dose préopératoire : réactualisation des résultats d’une série de 120 patientes
22. Rechute locale isolée après traitement conservateur pour un carcinome mammaire de stade I ou II, à propos de 57 patientes
23. 182MO Immune co-regulator (co-reg) expression in mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Anti-PD-(L)1-responders (R) versus (vs) non-responders (NR)
24. 584P Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy
25. 574P Myriad MyChoice plus intermediate performance to discriminate platinum-resistant high-grade ovarian cancer patients
26. 587P Sequential approach to determine the HRD status with BRCA1 promotor methylation status and shallow whole genome sequencing (sWGS)
27. 550P Immunoprofiling of mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Immune checkpoint inhibitor (ICI)-responders (R) versus non-responders (NR)
28. Cancer du col utérin stades IB et II opérable : comparaison rétrospective entre curiethérapie utérovaginale préopératoire et chirurgie première suivies d’une radiothérapie
29. Carcinomes épidermoïdes du col utérin opérables de stades IB et II de gros volume traités par irradiation première et chirurgie
30. 801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma
31. 741P Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study
32. 727P Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
33. PO-1135: Place of radiotherapy as part of multimodal management of cervical glassy cell carcinoma
34. 848P Features and clinical outcomes for younger women with epithelial ovarian cancer (EOC)
35. 135P - Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer
36. Changes in DNA damage response markers with treatment in advanced ovarian cancer
37. EP-1505: Multimodal management of locally advanced neuroendocrine cervical carcinoma
38. 1475PD - A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years
39. 948P - Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer
40. 939PD - An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer
41. PO-0962: Adjuvant brachytherapy as a part of a multimodal treatment for high-grade uterine sarcoma
42. 2705 The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO): How this organization changed management over the time for rare cancers
43. Dermatomyosite juvénile et lymphome T sous-cutané à type de panniculite. À propos dˈun cas
44. AGF-WS-9 Les lesions vulvo-vaginales : aspects en imagerie avec correlation anatomoclinique
45. Valeur pronostique de l'expression de COX-2 sur l'efficacité de la radiothérapie et sur la survie sans progression des patients atteints d'un glioblastome inopérable
46. L'expression cellulaire de hypoxia-inducible factor 1a (HIF-1a) prédit la réponse à la chimiothérapie des carcinomes du sein localement évolués
47. AGF3 Les masses pelviennes non gynecologiques mimant une origine gynecologique : aspects en imagerie avec correlation anatomo-pathologique
48. Tumeurs fonctionnelles ovariennes
49. Tumeurs mixtes mullériennes de l'endomètre. À propos de quatre cas développés sous tamoxifène: Gynecol Obstet Fertil 2003; 31: 733-738
50. Calrétinine et adénocarcinomes mammaires primitifs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.